A
Anne E. de Papp
Researcher at Merck & Co.
Publications - 32
Citations - 3732
Anne E. de Papp is an academic researcher from Merck & Co.. The author has contributed to research in topics: Osteoporosis & Femoral neck. The author has an hindex of 21, co-authored 32 publications receiving 3371 citations.
Papers
More filters
Journal ArticleDOI
Prevalence of Vitamin D Inadequacy among Postmenopausal North American Women Receiving Osteoporosis Therapy
Michael F. Holick,Ethel S. Siris,Neil Binkley,Mary K. Beard,Aliya Khan,Jennifer T. Katzer,Richard A. Petruschke,Erluo Chen,Anne E. de Papp +8 more
TL;DR: Prevalence of suboptimal 25(OH)D was significantly higher in subjects who took less than 400 vs. 400 IU/d or more vitamin D, and there was a significant negative correlation between serum PTH concentrations and 25( OH)D.
Journal ArticleDOI
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur
Dennis M. Black,Michael P. Kelly,Harry K. Genant,Lisa Palermo,Richard Eastell,Christina Bucci-Rechtweg,Jane A. Cauley,Ping Chung Leung,Steven Boonen,Arthur C. Santora,Anne E. de Papp,Douglas C. Bauer +11 more
TL;DR: The occurrence of fracture of the subtrochanteric or diaphyseal femur was very rare, even among women who had been treated with bisphosphonates for as long as 10 years, and the study was underpowered for definitive conclusions.
Journal ArticleDOI
Prevalence of vitamin D inadequacy among postmenopausal north american women receiving osteoporosis therapy
Michael F. Holick,Ethel S. Siris,Neil Binkley,Mary K. Beard,Aliya Khan,Jennifer T. Katzer,Richard A. Petruschke,Erluo Chen,Anne E. de Papp +8 more
TL;DR: More than half of North American women receiving therapy to treat or prevent osteoporosis have vitamin D inadequacy, underscoring the need for improved physician and public education regarding optimization of vitamin D status in this population.
Journal ArticleDOI
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Clifford J. Rosen,Marc C. Hochberg,Sydney Lou Bonnick,Michael R. McClung,Paul Miller,Susan B. Broy,Risa Kagan,Erluo Chen,Richard A. Petruschke,Desmond E. Thompson,Anne E. de Papp +10 more
TL;DR: Great gains in BMD and greater reductions in markers of bone turnover were seen with alendronate compared with risedronate with similar tolerability in a 12‐month head‐to‐head trial.
Journal ArticleDOI
A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover.
Andrew J. Burghardt,Galateia J. Kazakia,Miki Sode,Anne E. de Papp,Thomas M. Link,Sharmila Majumdar +5 more
TL;DR: A more pronounced response to ALN in the tibia than in the radius, driven by trabecular and endocortical changes is suggested, which is similar to that seen in women treated with an established antifracture therapeutic.